

(51) International Patent Classification:
Not classified(21) International Application Number:
PCT/US2024/032857(22) International Filing Date:
06 June 2024 (06.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/506,721 07 June 2023 (07.06.2023) US(71) Applicant: RAYZEBIO, INC. [US/US]; 5505 Morehouse
Dr, Suite 300, San Diego, California 92121 (US).(72) Inventors: NONCOVICH, Alain; 5505 Morehouse Dr,
Suite 300, San Diego, California 92121 (US). BHAT,
Abhijit; 5505 Morehouse Dr, Suite 300, San Diego,
California 92121 (US). HE, Rongjun; 5505 More-
house Dr, Suite 300, San Diego, California 92121 (US).
EHARA, Takeru; c/o PeptiDream, Inc., 3-25-23, Tono-
machi, Kawasaki-ku, Kawasaki-shi, Kanagawa 2100821
(JP). KOMURA, Rie; c/o PeptiDream, Inc., 3-25-23, Tono-
machi, Kawasaki-ku, Kawasaki-shi, Kanagawa 2100821
(JP). MIZUKOSHI, Yoshihide; c/o PeptiDream, Inc.,
3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kana-gawa 2100821 (JP). MORIMOTO, Kouki; c/o Pep-
tiDream, Inc., 3-25-23, Tonomachi, Kawasaki-ku, Kawa-
saki-shi, Kanagawa 2100821 (JP). TAKUWA, Masatoshi;
c/o PeptiDream, Inc., 3-25-23, Tonomachi, Kawa-
saki-ku, Kawasaki-shi, Kanagawa 2100821 (JP). YANAGI-
DA, Hayato; c/o PeptiDream, Inc., 3-25-23, Tonomachi,
Kawasaki-ku, Kawasaki-shi, Kanagawa 2100821 (JP).
OHUCHI, Masaki; c/o PeptiDream, Inc., 3-25-23, Tono-
machi, Kawasaki-ku, Kawasaki-shi, Kanagawa 2100821
(JP). NAGASAWA, Takayuki; c/o PeptiDream, Inc.,
3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kana-
gawa 2100821 (JP).(74) Agent: SCARR, Rebecca B. et al.; McNeill PLLC, 125
Cambridge Park Drive, Suite 301, Cambridge, Massachu-
setts 02140 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF




FIG. 4A

(57) Abstract: Provided herein are radiopharmaceuticals and conjugates,
and compositions thereof targeting GPC3 and uses thereof. In one as-
pect, provided herein are conjugates that comprise a peptide with avidity
to GPC3 and a metal chelator configured to bind with a radionuclide.
The conjugates described herein can further comprise a linker connecting
the chelator and the peptide. The conjugates described herein can further
comprise a radionuclide. In one aspect, provided herein are radiopharma-
ceuticals that comprise a peptide and a metal chelator bound to a radionu-
clide. The conjugates described herein can further comprise a linker con-
necting the chelator and the peptide. Further provided herein are methods
of treating cancer by administering the described radiopharmaceuticals,
conjugates, compositions thereof.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*